+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antimalarial Drugs Market by Drug Class, Route Of Administration, Formulation, Distribution Channel, End User - Global Forecast to 2030- Product Image
Antimalarial Drugs Market by Drug Class, Route Of Administration, Formulation, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Antimalarial Drugs Market by Drug Class, Route Of Administration, Formulation, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 193 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5967662
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antimalarial Drugs Market grew from USD 1.76 billion in 2024 to USD 1.87 billion in 2025. It is expected to continue growing at a CAGR of 5.95%, reaching USD 2.50 billion by 2030.

Setting the Stage for Antimalarial Market Dynamics

Over the past decade, malaria has persisted as a formidable global health threat, prompting concerted efforts from governments, non­governmental organizations, and private industry to innovate treatment protocols and fortify supply networks. Advances in pharmacological research have led to the development of novel combination therapies that target resistant Plasmodium strains while minimizing adverse effects, ushering in a new era of treatment efficacy. Concurrently, heightened regulatory scrutiny and evolving funding landscapes have introduced layers of complexity that require strategic agility. Policy shifts in key endemic regions and fluctuations in donor commitments further underscore the importance of data­driven decision making.

This executive summary distills the core findings of a rigorous market analysis, offering an integrative perspective on transformative trends, regulatory impacts, segmentation dynamics, regional nuances, competitive positioning, and strategic recommendations. By melding qualitative insights from industry experts with quantitative data from a multifaceted research framework, this document equips decision­makers with the clarity needed to navigate uncertainties and capitalize on emerging opportunities within the antimalarial drugs market. Through this lens, stakeholders can craft informed strategies that balance patient outcomes with sustainable commercial performance.

Embracing Technological and Strategic Breakthroughs in Antimalarials

In recent years, breakthroughs in drug discovery platforms and formulation science have reshaped the antimalarial landscape, enabling the development of therapies with extended half­life profiles and improved patient adherence. Next­generation combination regimens are leveraging artificial intelligence and high­throughput screening to identify synergistic molecules capable of overcoming multi­drug resistance. Beyond pharmaceuticals, digital supply chain solutions are streamlining distribution in remote regions, while real­time surveillance systems enhance outbreak response and ensure targeted therapy delivery.

Partnership models have also evolved, with public­private collaborations accelerating clinical trials and fostering technology transfer to endemic regions. Innovative financing mechanisms, such as advance market commitments and outcome­based agreements, are de­risking investments and aligning commercial incentives with public health goals. Furthermore, the integration of community health worker networks and telemedicine platforms is expanding treatment reach and adherence monitoring. These transformative shifts reflect a market in flux-one defined by convergence of scientific ingenuity, cross­sector collaboration, and technological integration.

Assessing the Ripple Effects of 2025 US Tariffs on Antimalarial Supply Chains

The introduction of new tariffs on imported active pharmaceutical ingredients and finished formulations in 2025 is poised to reverberate across the antimalarial supply chain, elevating raw material costs and reshaping procurement strategies. Manufacturers reliant on overseas API suppliers will confront margin pressures unless they adopt mitigation tactics such as tariff engineering or diversified sourcing arrangements. Higher production costs may translate into upward pricing adjustments, potentially exacerbating access challenges in low­resource settings and pressuring government procurement budgets.

Simultaneously, distributors and end users will need to recalibrate inventory management and logistics operations to absorb incremental duties without compromising treatment continuity. Some companies may accelerate local manufacturing ventures or finalize joint­venture agreements to circumvent tariff constraints, while importers explore bonded warehouse solutions to streamline duty deferral. Policymakers must consider the public health implications of these fiscal measures, as price escalations could undermine ongoing eradication initiatives. In this context, proactive stakeholder engagement and agile supply chain restructuring are essential to minimize disruption and sustain momentum toward global malaria control objectives.

Unveiling Critical Market Segments That Drive Demand and Innovation

Segmenting the antimalarial drugs market reveals distinct value pools and tailored growth vectors across therapeutic classes, administration routes, formulations, distribution pathways, and end­user settings. Within the drug class category, artemisinin­based combination therapy commands the lion’s share of development focus, driven by subsegments such as artemether­lumefantrine, artesunate­amodiaquine, artesunate­mefloquine, and dihydroartemisinin­piperaquine that offer enhanced efficacy against resistant strains. Non­artemisinin therapies maintain strategic relevance, with legacy compounds like chloroquine, mefloquine, primaquine, and quinine serving specialized roles in radical cure and prophylaxis protocols.

Administration route analysis highlights that injectable formulations remain indispensable for severe malaria cases in hospital environments, whereas oral therapies represent the backbone of outpatient treatment in community and primary care settings. Formulation preferences further delineate market opportunities: tablets dominate large­scale distribution due to ease of storage and transport, suspensions cater to pediatric dosing requirements, and injectables deliver critical rapid­onset action when intravenous or intramuscular delivery is mandated.

In distribution, hospital pharmacies facilitate acute care dispensing under clinical oversight, online pharmacies are emerging as convenient channels for remote regions with regulatory leniency, and retail pharmacies ensure broad community access for routine prevention and treatment. Finally, end­user analysis underscores the importance of ambulatory care centers in managing uncomplicated malaria and streamlining referrals, clinics in implementing targeted intervention campaigns, and hospitals in delivering intensive management for severe or complicated cases. This multidimensional segmentation framework empowers stakeholders to refine product portfolios, optimize channel strategies, and align resource allocation with distinct market realities.

Regional Perspectives Shaping Global Antimalarial Strategies

Regional dynamics exhibit nuanced drivers of demand, regulatory complexity, and competitive intensity that shape the global antimalarial market. In the Americas, public health funding in countries like Brazil and Colombia underscores a dual mandate of malaria control and economic development, while the United States sustains robust R&D investments and philanthropic contributions. Europe, Middle East & Africa present contrasting landscapes: stringent regulatory pathways and reimbursement frameworks in the EU coexist with acute supply chain constraints and high disease burden in sub­Saharan Africa. Collaborative initiatives under regional blocs and non­profit consortia aim to bolster manufacturing capacity and streamline cross­border distribution.

Across Asia­Pacific, rapid growth in API production hubs such as India and China is enhancing cost competitiveness, while endemic nations in Southeast Asia emphasize combination therapies and digital health integration to elevate surveillance and adherence. Local partnerships and technology transfers are expanding production of essential medicines and strengthening regional value chains. These divergent regional profiles inform market entry strategies, alliance structures, and risk mitigation plans for organizations seeking global footprint expansion and balanced portfolio performance.

Profiling Industry Leaders at the Forefront of Antimalarial Development

Leading pharmaceutical and biotechnology companies have adopted differentiated strategies to secure competitive positioning in the antimalarial market. Novartis is advancing its pipeline of single­dose radical cure candidates and exploring long­acting injectable formulations. Sanofi has forged alliances with global health organizations to fast­track field implementation in high­burden regions. GlaxoSmithKline leverages an extensive manufacturing network in emerging markets to optimize production costs and ensure supply continuity, while Cipla relies on strategic licensing agreements and targeted acquisitions to diversify its generic portfolio.

Viatris, following the merger of Mylan and Upjohn, has prioritized scale­up of injectables for severe malaria cases and expanded its portfolio to include novel formulations. Pfizer is integrating digital adherence tools as adjunct therapies, enhancing patient support and monitoring. Aspen Pharmacare is investing in regional API production to reduce dependency on external suppliers and fortify supply resilience. Across the board, these companies are focusing on regulatory harmonization, API diversification, and public­private partnerships to navigate evolving tariffs, address access challenges, and drive sustainable growth.

Strategic Imperatives for Strengthening Market Position and Patient Outcomes

Industry leaders must embrace a multifaceted strategy that aligns innovation, supply chain resilience, and stakeholder collaboration to thrive in the antimalarial market. Accelerating R&D efforts toward next­generation therapies, such as single­dose cures and long­acting injectables, will differentiate portfolios and address unmet clinical needs. Concurrently, investing in local manufacturing capabilities and forging strategic alliances can mitigate tariff impacts and ensure supply stability.

Digital transformation initiatives, including real­time tracking systems and adherence monitoring tools, can optimize distribution and elevate patient outcomes. Engaging proactively with policymakers and donor agencies will secure favorable regulatory pathways and align market access programs with public health objectives. Cultivating flexible pricing models and outcome­based agreements can unlock new funding channels while reinforcing corporate social responsibility commitments. By integrating these strategic imperatives within a coherent operational framework, organizations can enhance their competitive position, contribute to global malaria control goals, and drive long­term commercial success.

Robust Research Framework Enhancing Data Integrity and Insight Depth

This analysis is underpinned by a rigorous research methodology that synthesizes primary and secondary data sources. Primary research involved in­depth interviews with key opinion leaders, including clinical experts, policy makers, supply chain executives, and frontline healthcare providers across endemic and non­endemic regions. These qualitative insights were triangulated with quantitative data gathered from proprietary surveys targeting procurement officers and patient advocacy groups.

Secondary research encompassed a comprehensive review of regulatory filings, clinical trial registries, peer­reviewed journals, company disclosures, industry white papers, and global health organization reports. Data points were validated through cross­referencing multiple sources and applying statistical techniques to ensure consistency and reliability. Market segmentation was developed using a bottom­up approach, while thematic synthesis of qualitative findings provided contextual depth.

All findings were subjected to peer review by an internal advisory panel of industry veterans to eliminate bias and enhance analytical rigor. This multifaceted framework ensures that the insights presented herein are robust, actionable, and reflective of both current realities and emergent trends within the global antimalarial drugs landscape.

Concluding Synthesis of Antimalarial Market Evolution and Opportunities

In conclusion, the antimalarial drugs market stands at a pivotal juncture defined by scientific breakthroughs, shifting regulatory regimes, and new fiscal pressures. Emerging combination therapies and formulation innovations are expanding treatment possibilities, while evolving tariff structures demand agile supply chain strategies. Segmentation analysis reveals discrete value pools that warrant targeted commercialization tactics, and regional dynamics underscore the importance of localized partnerships and capacity­building initiatives.

Competitive intensity is at an all­time high as incumbent players and new entrants pursue differentiated portfolios and access programs. Yet, the convergence of public health imperatives and commercial incentives creates an unparalleled opportunity to advance malaria control and deliver sustainable growth. Stakeholders equipped with deep market insights, strategic foresight, and collaborative frameworks will be best positioned to navigate complexities, drive patient impact, and secure enduring market leadership.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Artemisinin Based Combination Therapy
      • Artemether Lumefantrine
      • Artesunate Amodiaquine
      • Artesunate Mefloquine
      • Dihydroartemisinin Piperaquine
    • Non Artemisinin Therapies
      • Chloroquine
      • Mefloquine
      • Primaquine
      • Quinine
  • Route Of Administration
    • Injectable
    • Oral
  • Formulation
    • Injectables
    • Suspensions
    • Tablets
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • End User
    • Ambulatory Care Centers
    • Clinics
    • Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Novartis International AG
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Cipla Limited
  • Viatris Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Ipca Laboratories Limited
  • Dr. Reddy's Laboratories Limited
  • Bayer Aktiengesellschaft

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antimalarial Drugs Market, by Drug Class
8.1. Introduction
8.2. Artemisinin Based Combination Therapy
8.2.1. Artemether Lumefantrine
8.2.2. Artesunate Amodiaquine
8.2.3. Artesunate Mefloquine
8.2.4. Dihydroartemisinin Piperaquine
8.3. Non Artemisinin Therapies
8.3.1. Chloroquine
8.3.2. Mefloquine
8.3.3. Primaquine
8.3.4. Quinine
9. Antimalarial Drugs Market, by Route Of Administration
9.1. Introduction
9.2. Injectable
9.3. Oral
10. Antimalarial Drugs Market, by Formulation
10.1. Introduction
10.2. Injectables
10.3. Suspensions
10.4. Tablets
11. Antimalarial Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Antimalarial Drugs Market, by End User
12.1. Introduction
12.2. Ambulatory Care Centers
12.3. Clinics
12.4. Hospitals
13. Americas Antimalarial Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Antimalarial Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Antimalarial Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis International AG
16.3.2. GlaxoSmithKline plc
16.3.3. Sanofi S.A.
16.3.4. Cipla Limited
16.3.5. Viatris Inc.
16.3.6. Pfizer Inc.
16.3.7. Sun Pharmaceutical Industries Limited
16.3.8. Ipca Laboratories Limited
16.3.9. Dr. Reddy's Laboratories Limited
16.3.10. Bayer Aktiengesellschaft
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ANTIMALARIAL DRUGS MARKET MULTI-CURRENCY
FIGURE 2. ANTIMALARIAL DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. ANTIMALARIAL DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ANTIMALARIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ANTIMALARIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTIMALARIAL DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE MEFLOQUINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CHLOROQUINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MEFLOQUINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PRIMAQUINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUININE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 50. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 52. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 53. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 55. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 59. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 60. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 62. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 88. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 91. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 95. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 96. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 98. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 101. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 102. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 103. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 105. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 109. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 112. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 115. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 116. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 117. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 119. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 123. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 124. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 126. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 133. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 136. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 137. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 140. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 143. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 144. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 147. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 150. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 151. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 152. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 154. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 157. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 158. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 161. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 165. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 166. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 168. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 171. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 172. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 173. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 175. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 182. SWEDEN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. SWEDEN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. NIGERIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 185. NIGERIA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 186. NIGERIA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 189. NIGERIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. NIGERIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 192. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 193. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 194. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 196. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. TURKEY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 199. TURKEY ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 200. TURKEY ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 201. TURKEY ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. TURKEY ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 203. TURKEY ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. TURKEY ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. ISRAEL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 206. ISRAEL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 207. ISRAEL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 210. ISRAEL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. NORWAY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 213. NORWAY ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 214. NORWAY ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 215. NORWAY ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. NORWAY ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 217. NORWAY ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. NORWAY ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. POLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 220. POLAND ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 221. POLAND ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 222. POLAND ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. POLAND ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 224. POLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. POLAND ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 228. SWITZERLAND ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 231. SWITZERLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. SWITZERLAND ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 241. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 242. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 243. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 244. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 246. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 249. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 250. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 251. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 253. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 256. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 257. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 258. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 259. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 260. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 267. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 268. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 274. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 281. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 283. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 284. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 285. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 286. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 287. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 288. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 291. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 292. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 293. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 294. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 295. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 296. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 297. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 298. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 299. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 300. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 301. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 302. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 303. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 304. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 305. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 306. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 307. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 308. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 309. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 310. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 311. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 312. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 313. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 314. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 315. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 316. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 317. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 318. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 319. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 320. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2030 (USD MILLION)
TABLE 321. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 322. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 323. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 324. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 325. ANTIMALARIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2024
TABLE 326. ANTIMALARIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

Companies Mentioned

The companies profiled in this Antimalarial Drugs market report include:
  • Novartis International AG
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Cipla Limited
  • Viatris Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Ipca Laboratories Limited
  • Dr. Reddy's Laboratories Limited
  • Bayer Aktiengesellschaft

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages193
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.87 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.5 Billion
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Anti-Malarial Medicines - Global Strategic Business Report - Product Image

Anti-Malarial Medicines - Global Strategic Business Report

  • Report
  • 288 Pages
  • Global
From
Aspergillosis Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Aspergillosis Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
India Antimalarial Drugs Market, By Region, Competition, Forecast & Opportunities, 2020-2030F - Product Image

India Antimalarial Drugs Market, By Region, Competition, Forecast & Opportunities, 2020-2030F

  • Report
  • 87 Pages
  • India
From
Antimalarial Agents. Design and Mechanism of Action - Product Image

Antimalarial Agents. Design and Mechanism of Action

  • Book
Pharmacokinetics and Pharmacodynamics of Antimalarial Drugs Used in Combination Therapy - Product Image

Pharmacokinetics and Pharmacodynamics of Antimalarial Drugs Used in Combination Therapy

  • Book
From

About the Antimalarial Market

The antimalarial market is a subset of the infectious diseases drugs market, which focuses on the treatment and prevention of malaria. Antimalarial drugs are used to treat and prevent the spread of the Plasmodium parasite, which is responsible for the disease. These drugs are typically administered orally, intravenously, or intramuscularly, depending on the severity of the infection. Common antimalarial drugs include chloroquine, artemisinin, and mefloquine. In addition to antimalarial drugs, the market also includes insecticides, insect repellents, and other preventive measures. These products are used to reduce the risk of infection by controlling the mosquito population, which is the primary vector for the Plasmodium parasite. Notable companies in the antimalarial market include GlaxoSmithKline, Sanofi, Novartis, and Merck. These companies produce a variety of antimalarial drugs, insecticides, and other preventive measures. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.